Motive and Telefónica have successfully completed a proof of concept (PoC) showcasing seamless authentication using GSMA Open Gateway's Number Verification API. Debuted at the Google Cloud booth ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a developer of targeted radiotherapies, announced the introduction of ATNM-400, a new radiotherapy for prostate cancer, and detailed ...

Actinium continues to advance ATNM-400 with additional data expected from Pluvicto-resistant prostate cancer models at AACR. Pluvicto (Lu-177-PSMA-617) is a prostate-specific membrane antigen (PSMA) ...

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a developer of targeted radiotherapies, announced the introduction of ATNM-400, a new radiotherapy for prostate cancer, and ...

Actinium has outlined its expanded market opportunities and expected 2025 milestones for each of its clinical programs as well as its R&D and radiopharmaceutical manufacturing capabilities as ...

Today is "Diabetes Alert Day" and health officials hope it will serve as a wake-up call to the millions of Americans who may have diabetes and don't know it yet. Diabetes is a group of diseases in ...

Risk Warning: Your Capital is at Risk. This iron ore trading guide focuses on the different ways you can trade iron ore as a commodity. We provide a list of regulated brokers in for traders who are ...

Sandesh Seth, Chairman and CEO at Actium Pharmaceuticals, Inc. commented: "We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating ...